Patent Assignment
Reel/Frame 057970/0314
Corrective Assignment to Correct the Assignee Name Servier Pharmaceuticals Llc by Removal of Comma and Updating Zip Code to 02210 Previously Recorded on Reel 056224 Frame 0921. Assignor(S) Hereby Confirms the Corrective Assignment.
Recorded: 2021-10-28
Pages: 34
Assignor
AGIOS PHARMACEUTICALS, INC.
Executed: 2021-03-29
Assignee
SERVIER PHARMACEUTICALS LLC
200 PIER FOUR BOULEVARD, 7TH FLOOR, BOSTON, MASSACHUSETTS, 02210
Covered Properties
(95)
Methods of Treating Cancer Having Somatic Mutations of the Isocitrate Dehydrogenase Gene
Application:
61/160,253 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/253,821 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/266,929 →
Methods and Compositions for Treating Cancer
Application:
61/160,664 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/266,930 →
Methods and Compositions for Treating Cancer
Application:
61/173,518 →
Methods of Treating Cancer Having Somatic Mutations of the Isocitrate Dehydrogenase Gene
Application:
61/180,609 →
Methods and Compositions for Treating Cancer
Application:
61/220,543 →
Methods and Compositions for Treating Cancer
Application:
61/227,649 →
Methods and Compositions for Treating Cancer
Application:
61/229,689 →
Methods and Compositions for Cell-Proliferation-Related-Disorders
Application:
61/253,820 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/256,396 →
Publication:
US US20120121515A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/939,519 →
Publication:
US US20140187435A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
16/790,860 →
Publication:
US US20200281501A1
Methods and Compositions for Cell-Proliferation-Related Disorders Characterized by a Neoactive Mutation at Residue 97 of IDH1 or at Residue 137 of IDH2
Application:
61/253,818 →
Therapeutically active compositions and their methods of use
Application:
61/285,122 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/313,532 →
Therapeutically Active Compositions and Their Methods of Use
Application:
13/492,159 →
Publication:
US US20130035329A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/377,485 →
Publication:
US US20170166541A1
Methods of Identifying a Candidate Compound
Application:
61/320,255 →
Methods of Identifying a Candidate Compound
Application:
61/331,322 →
Methods of Identifying a Candidate Compound
Application:
13/638,881 →
Publication:
US US20130197106A1
Therapeutically Active Compositions and Their Methods of Use
Application:
61/365,072 →
Therapeutically Active Compositions and Their Methods of Use
Application:
13/810,410 →
Publication:
US US20130184222A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/064,874 →
Publication:
US US20160264621A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/617,332 →
Publication:
US US20130288284A1
Methods and Compositions for Evaluating and Treating Cell Ptoliferation-Related Diorders Having an Isocitrate Dehydrogenase Neoactive Mutation
Application:
14/504,983 →
Publication:
US US20150240286A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/481,908 →
Publication:
US US20170210749A1
Therapeutically Active Compositions and Their Methods of Use
Application:
61/584,210 →
Therapeutically Active Compositions and Their Methods of Use
Application:
14/126,763 →
Publication:
US US20140213580A1
Therapeutically Active Compositions and Their Methods of Use
Application:
14/988,661 →
Publication:
US US20160130298A1
Therapeutically Active Compounds and Their Methods of Use
Application:
14/373,154 →
Publication:
US US20150087600A1
Therapeutically Active Compounds and Their Methods of Use
Application:
15/196,842 →
Publication:
US US20160304556A1
Therapeutic Compounds and Compositions
Application:
61/714,179 →
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Application:
61/845,286 →
Therapeutically Active Compounds and Their Methods of Use
Application:
14/341,426 →
Publication:
US US20150031627A1
Therapeutically Active Compounds and Their Methods of Use
Application:
15/347,407 →
Publication:
US US20170057994A1
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compositions and Their Methods of Use
Application:
61/942,170 →
Therapeutically Active Compounds and Their Methods of Use
Application:
62/081,537 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/942,172 →
Pharmaceutical Compositions of Therapeutically Active Compounds and Their Methods of Use
Application:
61/953,480 →
Pharmaceutical Compositions of Therapeutically Active Compounds
Application:
15/125,884 →
Publication:
US US20170007661A1
Pharmaceutical Compositions of Therapeutically Active Compounds
Combination Therapy for Treating Malignancies
Application:
62/242,267 →
Combination Therapy for Treating Malignancies
Application:
62/255,253 →
Combination Therapy for Treating Malignancies
Combination Therapy for Treating Malignancies
Application:
62/242,282 →
Combination Therapy for Treating Malignancies
Application:
16/846,976 →
Publication:
US US20200405737A1
Methods of Treatment of Malignancies
Application:
15/781,019 →
Publication:
US US20200268726A1
IDH1 Inhibitors for the Treatment of Haematological Malgnancies and Solid Tumors
Application:
16/079,802 →
Publication:
US US20190046512A1
IDH1 Inhibitors for the Treatment of Haematological Malignancies and Solid Tumors
Application:
16/869,238 →
Publication:
US US20200261434A1
Therapy for Treating Malignancies
Application:
62/682,808 →
Therapy for Treating Malignancies
Therapy for Treating Malignancies
Application:
17/203,433 →
Publication:
US US20210205281A1
Therapeutically Active Compounds and Their Methods of Use
Application:
63/149,075 →
Therapeutically Active Compounds and Their Methods of Use
Compounds and Their Methods of Use
Application:
61/729,321 →
Use of E-Cadherin and Vimentin for Selection of Treatment Responsive Patients
Application:
61/702,091 →
Use of E-Cadherin and Vimentin for Selection of Treatment Responsive Patients
Application:
61/805,512 →
Methods of Treating Cancer Having an Aberrant Egfr or Kras Genotype
Application:
13/249,609 →
Publication:
US US20120041070A1
Methods of Treating Cancer Having an Aberrant Egfr or Kras Genotype
Application:
61/165,387 →
Therapeutically Active Compositions and Their Methods of Use
Therapeutically Active Compositions and Their Methods of Use
Methods and Compositions for Cell-Proliferation-Related Disorders
Method for Diagnosing Cell Proliferation Disorders Having a Neoactive Mutation at Residue 97 of Isocitrate Dehydrogenase 1
Methods and Compositons for Cell-Proliferation-Related Disorders
Method for Treating Cell Proliferation Related Disorders
Methods for Diagnosing Idh-Mutant Cell Proliferation Disorders
Phenyl and Pyridinyl Substituted Piperidines and Piperazines as Inhibitors of IDH1 Mutants and Their Use in Treating Cancer
Therapeutically Active Compositions and Their Methods of Use
Therapeutically Active Compositions and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Therapeutic Compounds and Compositions
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutants Inhibitors for the Treatment of Cancer
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Pharmaceutical Compositions of Therapeutically Active Compounds
Pharmaceutical Compositions of Therapeutically Active Compounds
Pharmaceutical Compositions of Therapeutically Active Compounds
Combination Therapy for Treating Malignancies
Compounds and Their Methods of Use
Glutaminase Inhibitors and Method of Use
Glutaminase Inhibitors and Method of Use
Methods of Evaluating Patients Using E-Cadherin and Vimentin
Methods of Evaluating Patients Using E-Cadherin or Vimentin
Compounds and Their Methods of Use
Compounds and Their Methods of Use
Compounds and Their Methods of Use
Compounds and Their Methods of Use
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 29, 2009
From: SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023712/0029 →
Assignment of Assignor's Interest
Feb 12, 2010
From: SU, SHINSAN; DANG, LENNY; GROSS, STEFAN; JIN, SHENGFANG
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023933/0736 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023931/0704 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023932/0407 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023932/0286 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023932/0212 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023932/0234 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023933/0428 →
Assignment of Assignor's Interest
Feb 12, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 023933/0409 →
Assignment of Assignor's Interest
Mar 4, 2010
From: SU, SHINSAN; DANG, LENNY; GROSS, STEFAN; JIN, SHENGFANG
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024029/0215 →
Corrective Assignment to Correct the Serial Number Previously Recorded on Reel 023933 Frame 0409. Assignor(S) Hereby Confirms the Assignment.
Mar 4, 2010
From: GROSS, STEFAN; JIN, SHENGFANG; SU, SHINSAN; FANTIN, VALERIA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024031/0777 →
Assignment of Assignor's Interest
Apr 8, 2010
From: SALITURO, FRANCESCO G.; SAUNDERS, JEFFREY O.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024204/0980 →
Assignment of Assignor's Interest
Jun 7, 2010
From: SU, SHINSAN; DANG, LENNY; GROSS, STEFAN; JIN, SHENGFANG
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024493/0850 →
Assignment of Assignor's Interest
Jun 10, 2010
From: SU, SHINSAN; DANG, LENNY; GROSS, STEFAN; JIN, SHENGFANG
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024512/0940 →
Assignment of Assignor's Interest
Jun 10, 2010
From: SU, SHINSAN; DANG, LENNY; GROSS, STEFAN; JIN, SHENGFANG
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 024512/0948 →
Assignment of Assignor's Interest
Mar 24, 2011
From: FANTIN, VALERIA; SU, SHINSAN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 026013/0650 →
Assignment of Assignor's Interest
Mar 24, 2011
From: FANTIN, VALERIA; SU, SHINSAN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 026013/0517 →
Assignment of Assignor's Interest
Mar 31, 2011
From: FANTIN, VALERIA; SU, SHINSAN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 026053/0538 →
Assignment of Assignor's Interest
Oct 18, 2011
From: POPOVICI-MULLER, JANETA
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 027078/0132 →
Assignment of Assignor's Interest
Nov 2, 2011
From: DANG, LENNY; FANTIN, VALERIA; GROSS, STEFAN; GYUNG, HYUN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 027163/0548 →
Assignment of Assignor's Interest
Aug 21, 2012
From: SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 028821/0742 →
Assignment of Assignor's Interest
Oct 12, 2012
From: VIVA BIOTECH LTD
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 029122/0390 →
Assignment of Assignor's Interest
Oct 12, 2012
From: SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 029122/0396 →
Assignment of Assignor's Interest
Oct 23, 2012
From: FANTIN, VALERIA; SU, SHIN-SAN MICHAEL
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 029171/0947 →
Assignment of Assignor's Interest
Mar 28, 2013
From: SCHRODINGER, LLC.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 030105/0940 →